Immuno-oncology: Understanding function and dysfunction

About this module

Dr Chris Parrish provides an overview of how the normal immune system functions, what immunosurveillance involves and how tumours escape from it.

CPD hours: 1


Dhodapkar M et al. (2003) Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med. 198: 1753-1757.

Guerra N et al. (2008) NKG2D-deficient mice are defective in tumour surveillance in models of spontaneous malignancy. Immunity 28: 571-580.

Koebel CM et al. Adaptive immunity maintains occult cancer in equilibrium state. Nature 450: 903-907.

Shankaran V et al. (2001) IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.


Finn OJ (2012) Understanding the function and dysfuntion of the immune system in cancer. Ann Oncol. 23 Suppl 8:viii 6-9.

Guillerey C et al. (2016) Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Cell Mol Life Sci. 73: 1569-1589.

Take the CPD Quiz

Sorry. You must be logged in to view this form.